Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

September 1, 2026Posted inBiotechnology

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases.

Post navigation

Previous Post
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
Next Post
Is Moderna, Merck’s mRNA cancer vaccine win the start of a ‘personalized medicine revolution’?

Recent Posts

  • Soil Hidden as a Reservoir of Toxin-Producing Fusarium Fungi in Northwest Spain
  • Dengue-Carrying Mosquitoes Signal High Yellow Fever Risk in Northern Ghana Outbreak Zone
  • 3D-Printed Melanoma Models Promise Better Drug Tests but Face an Analysis Bottleneck
  • Why Most HPV Infections Vanish While a Few Turn Deadly: New AI Models Aim to Predict the Difference
  • Smarter Forecasts, Sharper Storage: New Framework Sizes Shared Batteries for Wind-Solar- Thermal Clusters

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top